Company intelligence / Profile preview

Allarity Therapeutics

Boston, Massachusetts, United Statesallarity.com ↗

Ownership: Public · ALLR
Employees: ~50
Development stage: Phase 2

Overview

Ongoing Phase 2 clinical trial for stenoparib in advanced ovarian cancer showing promising results, with two patients exceeding 14 months on treatment. In early Phase 2 data from December 2023, one patient experienced a complete response and four had stable disease, with all five patients experiencing clinical benefit exceeding 20 weeks.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

dovitinib

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $20.1M
Total revenue: $0
Enterprise value: $25.4M

Beyond the preview

Go deeper on Allarity Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allarity Therapeutics.

Explore the full profile